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Abstract
Background: Cerebral cavernous malformations (CCM) present as either sporadic or autosomal
dominant conditions with incomplete penetrance of symptoms. Differences in genetic and
environmental factors might be minimized among first-degree relatives. We therefore studied
clinical expression in a family with several affected members.
Methods: We studied a three-generation family with the onset of CCM as a cerebral haemorrhage
in the younger (four-year-old) sibling. Identification and enumeration of CCMs were performed in
T2-weighted or gradient-echo MRIs of the whole brains. Genetic analysis comprised SCCP,
sequencing and restriction polymorphism of the Krit1 gene in the proband and at risk relatives.
Results: The phenotypes of cerebral cavernous malformations (CCMs) in carriers of Krit1
mutations were very variable. We identified a novel frameshift mutation caused by a 1902A
insertion in exon 17 of the Krit1 gene, which leads to a premature TAA triplet and predicts the
truncating phenotype Y634X. A very striking finding was the absence of both clinical symptoms and
CCMs in the eldest sibling harbouring the 1902insA.
Conclusions: Patients in this family, harbouring the same mutation, illustrate the very variable
clinical and radiological expression of a Krit1 mutation. The early and critical onset in the proband
contrasts with minor clinical findings in affected relatives. This consideration is important in genetic
counselling.
Background
Cerebral cavernous malformations (CCM) are enlarged
capillary cavities without alterations in the surrounding
brain parenchyma. Studies based on necropsy and mag-
netic resonance imaging indicate a prevalence in the gen-
eral population close to 0.1–0.5 percent. CCMs present as
either sporadic or autosomal dominant conditions with
incomplete penetrance of symptoms such as epilepsy,
headaches, seizures and cerebral haemorrhage. Neuroim-
aging penetrance of CCMs is much higher than clinical
penetrance and almost 60% of at-risk relatives are symp-
tom-free in spite of having MRI lesions [1]. Sporadic CCM
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images of multiple lesions are found in inherited CCM
[1].
Mutations causing premature termination triplets in
CCM1, the gene encoding the Krit1 protein, cause heredi-
tary cavernous angiomas [2,3], and a germline mutation
in the KRIT1 gene has been reported to cause multiple
lesions in one CCM patient [4]. A great variety of muta-
tions have been described [5], including a redundant
mutation in Hispano-Mexican families corresponding to
a chromosomal haplotype that is not shared by patients of
Spanish extraction [6].
The Krit1 protein was identified by its interaction with
Rap1A, a small Ras like GTPase [7]. Four novel coding
exons and other non-coding exons have been described
by computational and experimental analyses [8,9]. KRIT1
encodes a 736 amino-acids protein containing four
ankyrin domains, a FERM domain and a C-terminal por-
tion that interacts with Rap1A. The four novel exons
encode an N-terminal region containing an NPXY motif
that is required for interaction of with icap1α, a modula-
tor of β1 integrin [10,11].
We report a mutation causing a premature termination tri-
plet in exon 17 of the Krit1 gene in a family with diag-
noses of cerebral cavernous angioma. The early onset in
the proband contrasts with minor symptoms in relatives
who are carriers of the mutation. Particularly striking is
the absence of CCMs in the eldest sibling.
Methods
Patients
The onset of the disease in this family was a cerebral
haemorrhage in the younger sibling, the 4-year-old
proband. The family comprises a three-generation pedi-
gree with minor neurological symptoms in the anteced-
ents. Antecedents were assessed by a retrospective clinical
study that revealed three asymptomatic siblings and non-
specific symptoms in other affected relatives (his sister
and grandmother) who complained about headaches.
Identification and enumeration of CCMs were performed
in T2-weighted or gradient-echo MRIs of the whole brains.
Genetic analysis
CCM1 haplotypes of individuals of the CVE10 family
were analyzed using the protocols and primers of a set of
polymorphic microsatellite markers spanning the CCM1
interval, as previously described [12].
A fragment of the Krit1 gene containing exon 17 was PCR-
amplified with forward (5'TGGTACATTTTCCTTTCA) and
reverse (5'TGACATGATTGGTAAAAA) primers. The
nomenclature of the cDNA refers to the full length KRIT1
cDNA in GenBank (accession number AF296765).
Genomic DNA was initially screened by analysis of SSCP.
PCR fragments were denatured at 95°C for 5 min, ice
chilled, and separated by electrophoresis in 10% acryla-
mide-bisacrylamide (37.5:1) gels containing 10% glycerol
without urea.
Sequencing of exon 17 was carried out in genomic DNA
by the terminal dideoxynucleotide method. Automated
sequence analyses of both the sense and antisense strands
were done with 5'-labeled IRD800 primers according to
the protocols of the SequiTherm kit (Epicentre Technolo-
gies, Madison, Wisconsin). Polyacrylamide gel electro-
phoresis and analysis of the sequencing fragments were
performed in a LI-COR DNA4000 sequencer with the soft-
ware provided by the manufacturer (LI-COR Inc, Lincoln,
Nebraska, Canada).
Table 1: Location and number of cerebral malformations. MRIs were obtained with echo-gradient sequences except the T2-weighted 
images of patient I-1. Individual II-5 is the proband's uncle, not shown in figure 1, who harbours the 1902insA mutation. MRIs of sibling 
III-2 were repeatedly negative and therefore he was excluded from the table.
I-1 II-1 II-5 III-3 III-4 III-5 %
Age 82 46 52 15 11 4
Onset age 67 --- 39 --- 9 4
Symptoms Headache None Hemorrhage none Headache Hemorrhage
Total 34 51 37 5 9 8 100
Frontal 8 21 14 1 1 1 32
Parietal 10 12 10 1 1 2 25
Temporal 4 8 6 2 2 4 18
Occipital 5 5 3 0 4 0 12
Diencephalon 0 1 1 1 0 0 2
Midbrain 1 0 0 0 0 0 0.7
Pons 0 1 1 0 1 0 2
Medulla 0 1 0 0 0 0 0.7
Cervical 6 2 2 0 0 1 7.6Page 2 of 6
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The onset of cerebral hemorrhage in the 4-year-old
proband was the main clinical finding in the CVE10 fam-
ily. The retrospective study of siblings and parents showed
minor symptoms though one sibling had epilepsy. The
clinical study was completed with MRI scans of consent-
ing symptomatic and asymptomatic at-risk first-degree
relatives. Multiple CCMs were observed in the MRIs of the
grandmother, mother and two of the siblings and there-
fore familial characteristic was confirmed (see table 1 and
figure 1 for details of number and locations of CCMs).
The number of CCMs in patients of this pedigree was
related to age with a ratio around 0.9 (range 0.3–2) and
no significant differences in location were observed. Com-
parison of CCM locations is weakened because there were
far fewer malformations in the younger patients (table 1).
Haplotyping of markers of the locus demonstrated segre-
gation linkage of this family to CCM1. The affected indi-
viduals, i.e. those with CCMs in MRIs, shared the same
grandmother's chromosome. It is worth noting that the
asymptomatic sibling III-2 shares the linked haplotype,
without apparent recombination, but his MRI showed no
CCMs. Sequencing of the forward and reverse strands of
the proband demonstrated an exonic A/T insertion at
position 1902 leading to a premature TAA termination
codon and the predicted phenotype Y634X. The 1902A
insertion and the ambiguities of the overlapping strands
were identified in both the sense and antisense strands.
The nucleotide insertion at this position originates a TTAA
MRIs of CCMsFigure 1
MRIs of CCMs. The echo gradient sequences of the proband (left), grandmother (middle) and the older brother (right) harbour-
ing the Y634X mutation (III-2 in figure 3). Note the typical images of cavernous malformation and the absence of lesions in III-
2, the asymptomatic carrier of the 1902insA.
Left panel, SCCP of the proband and parents of CVE10 PCR was p rformed with the reactio  mixture supplemented with [α32P]-dCTPFigure 2
Left panel, SCCP of the proband and parents of CVE10 PCR was 
performed with the reaction mixture supplemented with 
[α32P]-dCTP. Aliquots of the product were run in acrylamide 
gels (see Methods) and revealed by auto-radiography. Right 
panel, chromatogram of the 1902InsA. Traces of the sense 
(upper) and antisense (lower) DNA strands of the proband. 
The wild type and mutated nucleotide sequences and the 
aminoacid change are indicated over the sense strand. The 
sequence shows the site of the 1902insA mutation (see 
arrow) and the frameshift. The ambiguities are caused by the 
overlapping bands of the wild type and mutated strands due 
to the nucleotide insertion. The stop TAA triplet predicts a 
truncating protein with the changed phenotype Y634X.
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BMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/5Haplotypes and restriction fragment polymorphism (RFLP)Figure 3
Haplotypes and restriction fragment polymorphism (RFLP). Haplotypes were analysed using the markers surrounding CCM1 as 
described in Methods. The markers from top to bottom were: D7S2409, D7S1813, D7S1789, D7S646, D7S558, D7S689, 
D7S652 and D7S492. Exon 17 was amplified with the primers and aliquots of the PCR were digested overnight at 37°C with 
MseI. The fragments were separated in an 8% polyacrylamide gel containing urea and, after staining with ethidium bromide, the 
gel was photographed under UV. The undigested product is 297 pb long and the fragments separated from the TTAA restric-
tion site are 158 and 139 pb. Therefore, individuals harbouring the 1902insA mutation have three fragments of 297, 158 and 
139 bp. Filled symbols in the pedigree refer to patients with CCMs in the echo-gradient MRIs. Arrow indicates the proband. 
Stairs refer to asymptomatic carriers of the mutation. The double stair denotes the asymptomatic carrier with MRIs free of 
CCMs
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BMC Neurology 2003, 3 http://www.biomedcentral.com/1471-2377/3/5restriction. This is recognised by the MseI endonuclease
that splits the 297 bp PCR product into 158 and 139 bp.
The RFLP of exon 17 in affected CV10E individuals dem-
onstrated a heterozygous polymorphism of 297, 158 and
139 bp. Here again, the second brother (individual III-2 in
the pedigree) had the mutated polymorphism although
his MRI was free of CCMs. There is a complete
coincidence of the CCM-linked haplotype with the
mutated RFLP in this pedigree (see figure 3). Analysis of
the chromosomes of 80 healthy individuals (not shown)
coincided with the wild type RFLP.
Discussion
Hereditary forms of CCM, in contrast to sporadic forms
that are characterized by single lesions, present as multi-
ple malformations and, frequently, two or more relatives
are affected [1]. This family illustrates the very variable
clinical phenotype of cavernous malformations since the
proband is the younger sibling suffering a cerebral hemor-
rhage. This early and critical onset contrasts with the
minor symptoms observed in the affected relatives, even
in the 82-year-old grandmother, notwithstanding the
multiple cerebral lesions. However, the most striking find-
ing was that repetitive studies of brain images of the III-2
sibling, who is 18 years old, demonstrated no
malformations in spite of the presence of the 1902A inser-
tion. The absence of cavernous malformations in echo-
gradient sequences in this sibling was confirmed by MRIs
of the spinal cord and the genetic status was corroborated
by the inheritance of the haplotype harbouring the muta-
tion and its illustration with MsI restriction polymor-
phisms. Nonetheless small CCMs, undetectable even on
gradient echo sequences, could still be present in the eld-
est sibling and might develop later.
Several mutations in exon 17 of the Krit1 gene associated
with CCMs have been described [5]. The Y634X mutation
modifies the FERM sequence in the last residues
(IPTYGAA), which are replaced by YPT*WSS, indicating
the potential pathogenic mechanism of the FERM
domain. The report of a novel N-terminal region in Krit1
containing an NPXY motif interacting with icap1α, a
modulator of β1 integrin, and the presence of a FERM
domain in Krit1, have suggested that this protein might be
involved in bi-directional signaling between the integrin
and the cytoskeleton [11].
Penetrance of Krit1 mutations has not been properly stud-
ied but significant locus-specific differences in penetrance
have been identified. The penetrance of clinical CCMs
among apparent carriers in kindreds linked to CCM1,
CCM2 and CCM3 have been estimated as 88, 100 and
63% respectively [13]. Individuals usually become
symptomatic between 20 and 40 years of age, although
clinical signs have been described in all age groups [1,5].
Asymptomatic carriers are probably not an unusual find-
ing, but the demonstration of the mutation is necessary to
raise this conclusion and for genetic counselling. CCMs
may develop in utero decades before any clinical presenta-
tion [3] but it is possible that penetrance varies among
families with particular mutations at each gene. Small cav-
ernomas could be present in the eldest sibling of the fam-
ily studied here and may develop later. Nonetheless, the
variable clinical and radiological traits in affected individ-
uals of the same family exclude a direct correlation
between clinical expression and genotype. The affected
siblings, in addition to the Y634X mutated phenotype,
share the same paternal chromosome, so a variable
genetic background, at least in the vicinity of CCM1, can
be excluded.
Assuming a pathogenic mechanism similar to the double-
hit hypothesis of tumorigenesis and given the multiplicity
of lesions, a very potent susceptibility to genetic or envi-
ronmental factors is required to cause the multiplicity of
somatic events. Differences in genetic and environmental
factors are presumably minimal among first-degree rela-
tives and therefore cannot easily explain the variable clin-
ical and radiological expression. In addition to genetic
and environmental causes, epigenetic factors and other
mechanisms, i.e. non-sense mRNA decay, can be consid-
ered in the pathogenesis of CCM.
Conclusions
Patients in this family, harbouring the same mutation and
chromosomes, are illustrative of the very variable clinical
and radiological expression of a Krit1 mutation. The early
and critical onset in the proband contrasts with minor
clinical findings in the affected relatives. This considera-
tion is important in genetic counselling.
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